ASH 2016

ASH 2016

Fred Hutchinson Cancer Research Center experts are presenting pioneering findings across the field of hematology — from the unique genomic properties of pediatric acute myeloid leukemia to promising immunotherapy clinical trial results — at the 58th American Society of Hematology Annual Meeting Dec. 3–6, 2016.

Highlights include:

  • Latest immunotherapy trial results for patients with advanced leukemia
  • First results of early phase trial show 100 percent remission rate using T-cell therapy for AML patients
  • Massive pediatric AML genomic sequencing effort reveals
  • GVHD study so successful it was closed early and brought to clinic
  • Leading the way on cord blood transplantation

Coverage From ASH

FOR THE MEDIA

Hutch Team

For more information or to arrange an interview, please contact Fred Hutch at 206.667.2210 or email our media relations team.

ASH In The News

Early-phase CAR T-cell therapy produces promising results in CLL patientsDec. 7, 2016 | Life Sciences Daily

T-Cell Therapy, a Promising Panacea for Leukemia?
Dec. 6, 2016 | Arrianne Nellaine del Rosario | Nature World News

Immunotherapy shows promise in preventing leukemia relapse
Dec. 6, 2016 | MedicalXpress

New immunotherapy shows hope in preventing leukemia relapse
Dec. 6, 2016 | Business Standard

Top barriers to fully utilizing precision medicine biomarkers
Dec. 6, 2016 | Bryant Furlow | Managed Healthcare Executive

ASH 2016: CD19-Targeting CAR T-Cell Immunotherapy Yields High Response Rates in Treatment-Resistant CLL
Dec. 5, 2015 | The ASCO Post

Marie Bleakley, MD, PhD, on GVHD: Reducing Rates and Increasing Survival
2016 ASH | The ASCO Post

Brenda Sandmaier, MD, and Sagar Lonial, MD, on Preventing GVHD: Clinical Trial Results
2016 ASH | The ASCO Post

Fred Hutch research shows immunotherapy could prevent Leukemia patients from relapsing
Dec. 5, 2016 | Clare McGrane | GeekWire

The Xconomy Immuno-Oncology Resource: A Mid-ASH T Cell Update
Dec. 5, 2016 | Alex Lash | Xconomy

CAR T-Cell Immunotherapy Proves a Plus in Treatment-Resistant Chronic Lymphocytic Leukemia
Dec. 5, 2016 | Genetic Engineering & Biotechnology

Can CAR-T cancer treatments be fine-tuned to avoid toxic side effects?
Dec. 5, 2016 | Arlene Weintraub | FierceBiotech

ASH16 Preview: New CAR T-cell Data Come at a Pivotal Moment (requires login, but available to general public)
Dec. 1, 2016 | Miguel-Angel Perales, MD | Medscape